| 17.96 0.09 (0.5%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.09 | 1-year : | 24.63 |
| Resists | First : | 18.05 | Second : | 21.09 |
| Pivot price | 16.68  |
|||
| Supports | First : | 15.85 | Second : | 14.5 |
| MAs | MA(5) : | 17.58 |
MA(20) : | 16.31 |
| MA(100) : | 12.84 |
MA(250) : | 11.79 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 93.2  |
D(3) : | 93.4 |
| RSI | RSI(14): 86.6 |
|||
| 52-week | High : | 18.05 | Low : | 8.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ROIV ] has closed below upper band by 4.8%. Bollinger Bands are 97.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 32 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.99 - 18.04 | 18.04 - 18.1 |
| Low: | 17.48 - 17.54 | 17.54 - 17.62 |
| Close: | 17.84 - 17.94 | 17.94 - 18.05 |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Tue, 21 Oct 2025
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) - Yahoo
Mon, 20 Oct 2025
Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing The 16% Potential Upside - DirectorsTalk Interviews
Tue, 14 Oct 2025
Positive Phase 3 Data and Analyst Support Could Be a Game Changer for Roivant Sciences (ROIV) - Sahm
Tue, 14 Oct 2025
A Look at Roivant Sciences’s Valuation Following Positive Phase 3 Result for Brepocitinib - Sahm
Sun, 05 Oct 2025
Why Roivant Sciences (ROIV) Is Up 6.6% After Positive Phase 3 Brepocitinib Results and SEC Filing - Sahm
Tue, 23 Sep 2025
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 683 (M) |
| Held by Insiders | 4.1769e+008 (%) |
| Held by Institutions | 26.1 (%) |
| Shares Short | 39,050 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.15e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 839.7 % |
| Return on Equity (ttm) | -12.6 % |
| Qtrly Rev. Growth | 2.323e+007 % |
| Gross Profit (p.s.) | -60.67 |
| Sales Per Share | -15.13 |
| EBITDA (p.s.) | -4.63283e+008 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -851 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.19 |
| Price to Cash Flow | 3.38 |
| Dividend | 0 |
| Forward Dividend | 2.797e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|